Tagged with Biotech,

local company Turkey’s leading pharmaceutical company is in the process of developing production facilities abroad, and it has just begun construction of a USD 100 million biotech facility; CEO Süha Taşpolatoğlu believes that these two steps will help bring the company closer to its aspiration of becoming a pharmaceutical player on the…

biotech Local flagship company Boryung has found success with its newly developed angiotension receptor blocker (ARB) Kanarb. Nine molecules currently exist worldwide in this category of antihypertensives, and Kanarb is currently ranked eighth. “Boryung is the only domestic company that has developed a drug from start to finish, including outlicensing. Of…

Samsung Korea’s economy has been dominated for decades by chaebols, large family-owned business conglomerates like Samsung, Hyundai, and LG, known for their hierarchical structures and success in Korea’s traditional sectors. However, a number of these big businesses are today making investments in the life sciences area – and those that started…

biotech Medytox is the most valuable pharmaceutical business in Korea, with a highly successful botulinum toxin product on the market, and can only grow further when they finish development of their second generation botulinum toxin product that will be commercialized globally (outside of Japan and Korea) by Botox manufacturer Allergan. What…

infrastructure Dogan Taşkent, president of the Swiss Chamber of Commerce in Turkey discusses the most successful models for innovation in Turkey, the current status of start-up incubators in the country, and how Turkey can learn from the Swiss model for innovation. What are the main economic challenges that Turkey is facing…

Genzyme Genzyme Turkey’s general manager discusses diagnosis and treatment access issues for rare diseases, the need for prioritization of patient welfare in all aspects of health policy, and the importance of the Turkish market and its potential to Genzyme globally. For rare diseases, do Turkish patients have adequate access to the…

biotech Landsteiner is betting on biotech and genomics. The head of new developments and the head of genomic research share their views on the future of the company as well as the importance of embedding new technology in new product developments to better adapt to the changing needs of the Mexican…

biotech As in human health, innovation is key in the animal health industry. The CEO and second generation at the head of Tornel presents the company’s most important milestones since its establishment back in 1976, how the Group started export operations to the Middle East as well as how it is collaborating…

biotech SillaJen’s CEO shares his passion for his companies oncolytic vaccinia virus, and its potential to revolutionize the treatment of solid tumor cancers, even arguing that it may eventually constitute ‘a cure for cancer’.   Could you please introduce yourself Dr. Moon, and tell us how you became involved with SillaJen? …

biotech On February second, the Korean Ministry of Health and Welfare announced the start of a second round of financing to the biopharmaceutical industry, as part of the Global Pharmaceutical Industry Development Fund (GPIDF). A total of USD 123 million will be invested in Korean pharmaceutical and biotech companies for the…

biotech The executive managing director of a leading American healthcare provider offering an innovative range of products on the local Algerian market treating asthma, diabetes, hepatitis and cholesterol speaks about the company’s experience and the country’s ambition to become a biotech leader For the pharmaceutical industry, the African continent – especially…

biotech Biograft is the first private tissue bank in Mexico meeting the increasing demand for implants of human musculoskeletal tissue. The general director and founder discusses the vision behind the creation of Biograft, how the company mastered to overcome skepticism and the plans to expand exports and transform the company in…